

Summary

	Screening	Baseline	FU mo.1	FU mo.6	FU mo.12	FU mo.18	FU mo.24
Consent form	X						
Height & weighth	X						X
BP & HR	X		X	X	X	X	X
ABPM		optional			optional		optional
EKG	X	only cardioverted pts			x		x
Echocardiography	X		only cardioverted pts in sinus rhythm	only PA	only PA		
Clinical chemistry		X	only PA		only PA		X
Drugs		X	only PA or cardioverted pts	X	X	X	X
Arterial Stiffness (if instrumentation is available)		X	only PA		only PA		X
EchoDoppler carotid arteries		optional					optional
QoL		X	only PA or cardioverted pts		X		X
MACE			only PA or cardioverted pts	X	X	X	X
Collect plasma & urine for centralized assays		X	only PA		only PA		X

FU: Follow-up; mo: month; MACE: main adverse cardiovascular events; PA: primary aldosteronism; pt: patient; QoL: Quality of Life Questionnaire.

 all patients
  optional
  only PA patients
  only cardioverted pts in sinus rhythm or PA patients

Clinical chemistry

	Screening	Baseline	FU mo.1	FU mo.12	FU mo.24
S-Glucose		x	x	x	x
S-HbA1c		x	x	x	x
S-Triglycerides		x			x
S-Cholesterol		x			x
S-HDL-C		x			x
S-LDL-		x			x
S-Creatinine		x	x	x	x
e-GFR		x	x		x
S-TSH		x			x
INR		x			x
S-Homocysteine		x			x
S-NT-proBNP		x	x	x	x
S-TnI or TnT		x			x
S-PTH		x			x
S-25OHvitamin D3		x			x
S-Na+		x	x	x	x
S-K+		x	x	x	x
S-ionized Ca2+		x	x	x	x
U-Na+		x	x	x	x
U-K+		x	x	x	x
U-Na+ /24h		x	x	x	x
U-K+/24h		x	x	x	x
Microalbuminuria/creatinine		x			x
PRA basal		x	x	x	x
PRA captopril		x	x	x	x
DRA basal		x	x	x	x
DRA captopril		x	x	x	x
S-Aldosterone basal		x	x	x	x
S-Aldosterone captopril		x	x	x	x
S-Cortisol		x			x
PRA post CV		x			
DRA post CV		x			
S-Aldosterone post CV		x			
U-Metanephrine/24h		x			
U-Normetanephrine/24h		x			